Resistance in nonfermenting gram-negative bacteria: Multidrug resistance to the maximum

被引:69
作者
McGowan, John E., Jr. [1 ]
机构
[1] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA
关键词
D O I
10.1016/j.ajic.2006.05.226
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Nonfermenting gram-negative bacteria pose a particular difficulty for the healthcare community because they represent the problem of multidrug resistance to the maximum. Important members of the group in the United States include Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and Burkholderia cepacia. These organisms are niche pathogens that primarily cause opportunistic health care-associated infections in patients who are critically ill or immunocompromised. Multidrug resistance is common and increasing among gram-negative nonfermenters, and a number of strains have now been identified that exhibit resistance to essentially all commonly used antibiotics, including antipseudomonal penicillins and cephalosporins, aminoglycosides, tetracyclines, fluoroquinolones, trimethoprim-sulfamethoxazole, and carbapenems. Polymyxins are the remaining antibiotic drug class with fairly consistent activity against multidrug-resistant strains of P aeruginosa, Acinetobacter spp, and S maltophilia. However, most multidrug-resistant B cepacia are not susceptible to polymyxins, and systemic polymyxins carry the risk of nephrotoxicity for all patients treated with these agents, the elderly in particular. A variety of resistance mechanisms have been identified in P aeruginosa and other gram-negative nonfermenters, including enzyme production, overexpression of efflux pumps, porin deficiencies, and target-site alterations. Multiple resistance genes frequently coexist in the same organism. Multidrug resistance in gram-negative nonfermenters makes treatment of infections caused by these pathogens both difficult and expensive. Improved methods for susceptibility testing are needed when dealing with these organisms, including emerging strains expressing metallo-beta-lactamases. Improved antibiotic stewardship and infection-control measures will be needed to prevent or slow the emergence and spread of multidrug-resistant, nonfermenting gram-negative bacilli in the healthcare setting.
引用
收藏
页码:S29 / S37
页数:9
相关论文
共 62 条
[31]   Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B [J].
Landman, D ;
Bratu, S ;
Alam, M ;
Quale, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (06) :954-957
[32]   In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy [J].
Le Thomas, I ;
Couetdic, G ;
Clermont, O ;
Brahimi, N ;
Plésiat, P ;
Bingen, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) :553-555
[33]   Metallo-β-lactamase-producing gram-negative bacilli in Korean nationwide surveillance of antimicrobial resistance group hospitals in 2003:: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp. [J].
Lee, K ;
Ha, GY ;
Shin, BM ;
Kim, JJ ;
Kang, JO ;
Jang, SJ ;
Yong, D ;
Chong, Y .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 50 (01) :51-58
[34]   Hospital-acquired pneumonia in critically ill patients: Factors associated with episodes due to imipenem-resistant organisms [J].
Leroy, O ;
d'Escrivan, T ;
Devos, P ;
Dubreuil, L ;
Kipnis, E ;
Georges, H .
INFECTION, 2005, 33 (03) :129-135
[35]   Minimizing antimicrobial resistance: The key role of the infectious diseases physician [J].
McGowan, JE .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) :939-942
[36]   Control of antimicrobial resistance in the health care system. [J].
McGowan, JE ;
Tenover, FC .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1997, 11 (02) :297-+
[37]   Economic impact of antimicrobial resistance [J].
McGowan, JE .
EMERGING INFECTIOUS DISEASES, 2001, 7 (02) :286-292
[38]   Pseudomonas aeruginosa bloodstream infection:: Importance of appropriate initial antimicrobial treatment [J].
Micek, ST ;
Lloyd, AE ;
Ritchie, DJ ;
Reichley, RM ;
Fraser, VJ ;
Kollef, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (04) :1306-1311
[39]  
Michalopoulos A, 2005, CRIT CARE, V9, pR53, DOI 10.1186/cc3020
[40]   High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation [J].
Nakajima, A ;
Sugimoto, Y ;
Yoneyama, H ;
Nakae, T .
MICROBIOLOGY AND IMMUNOLOGY, 2002, 46 (06) :391-395